340B Drug Pricing Program
Since 1992, the federal 340B Drug Pricing Program has enabled eligible hospitals to buy outpatient prescription drugs at steep discounts, with the goal of expanding care for low-income, uninsured and vulnerable patients. A 2026 study by CancerCare and Pioneer Institute found that 340B hospitals provide, on average, less charity care and care for uninsured patients than non-340B hospitals.
340B Drug Pricing Program Resources
CancerCare has developed resources to help advocate for 340B program policy reform.
- The 340B Accountability Gap (White Paper from Pioneer Institute & CancerCare)
- CHARITY CARE GONE WRONG, The 340B Drug Pricing Program Is Failing Vulnerable Patients, But Policy Reform Can Help (two-pager)
- What Patients and Caregivers Should Know About 340B (two-pager)
Watch the webinar, The 340B Drug Pricing Program:
A Profitable Program Failing Vulnerable Patients
In this webinar recorded on June 4, 2026, CancerCare and Pioneer Institute shared
findings from their 340B study. They discuss their recommendations from the project’s study
on charity care and share patients’ voices on financial challenges and access barriers.
Bernetia was diagnosed with stage 2 HER2-positive breast cancer. After a few months of treatment, she was notified that her health care team was no longer in network, and the hospital informed her that she could not be seen unless she could pay.
Margarita shares the challenges she faced affording her medication, on top of her rent, groceries and other utilities, after she was diagnosed with acute lymphoblastic leukemia, and later brain cancer.
Both Bernetia and Margarita share their experiences receiving treatment from 340B hospitals, the financial challenges they faced in affording medication, and how the 340B hospitals failed to offer support.